Zantac State Court Litigation — Delaware and California 2026

Delaware Superior Court — The Center of Zantac Litigation in 2026

Delaware Superior Court has emerged as the primary coordinated venue for Zantac state court litigation. Delaware is a natural forum for Zantac claims because major pharmaceutical defendants — including Sanofi and GSK — are incorporated in Delaware, supporting personal jurisdiction without complex minimum contacts analysis. Delaware uses the Frye evidentiary standard for expert testimony, which asks whether the scientific methodology is generally accepted in the relevant community rather than whether the specific expert's analysis is reliable under the Daubert gatekeeping inquiry. Delaware courts have issued coordinated case management orders covering thousands of consolidated Zantac cases, established bellwether trial schedules, and ruled on preliminary expert challenges. As of 2026, Delaware proceedings are advancing toward trial on selected bellwether cases that will help establish the settlement value of the broader pool of claims.

California State Courts — Active Dockets and Favorable Rulings

California state courts have been an active venue for Zantac litigation since 2021. California uses the Kelly/Frye general acceptance standard for novel scientific evidence, which differs from federal Daubert. California courts in Los Angeles, San Francisco, and Sacramento counties have heard and denied multiple defense motions for summary judgment based on causation arguments, allowing cases to proceed to trial. California's broad discovery rules and well-developed pharmaceutical tort litigation bar have supported efficient case development. California's 2-year statute of limitations with the discovery rule governs claims — claimants diagnosed with cancer from 2022 onward who can demonstrate delayed discovery of the Zantac connection, or who were diagnosed more recently, have viable filing windows in 2026.

How State Court Litigation Proceeds Differently From the MDL

In the federal MDL, a single Daubert ruling on general causation applied to all plaintiffs simultaneously — a winner-take-all structure that enabled defendants to eliminate the entire MDL with a single favorable expert exclusion ruling. State courts typically proceed differently. Coordinated proceedings in state courts often involve bellwether trials — individual cases tried to verdict that help establish the settlement value range for the broader pool. Even in coordinated proceedings, each case is ultimately adjudicated on its own facts. A ruling excluding one expert's methodology does not automatically eliminate every other plaintiff's case, because different plaintiffs may have different expert witnesses, different cancer types with varying evidentiary support, and different state-specific admissibility standards.

Other Active State Court Venues in 2026

Beyond Delaware and California, individual Zantac cases have been filed in state courts in Texas, Florida, New Jersey, Pennsylvania, Illinois, New York, and other states with significant plaintiff populations. These individual state filings are not coordinated in the same way as Delaware and California, but they proceed under each state's own rules and evidentiary standards. For claimants in states outside Delaware and California, a pharmaceutical litigation attorney can evaluate whether filing in their home state court, or transferring to a Delaware or California coordinated proceeding, is the optimal strategic approach based on that claimant's specific circumstances.